Toremifene

證據等級: L5

預測適應症: 1 個

Toremifene: From Breast Cancer to HIV Infectious Disease

One-Sentence Summary

Toremifene is a selective estrogen receptor modulator (SERM) established in breast cancer treatment. The TxGNN model predicts it may be applicable in HIV Infectious Disease — most plausibly by addressing HIV-associated cryptococcal opportunistic infections rather than the virus itself. This direction is currently supported by 0 clinical trials and 1 preclinical publication, placing the evidence at an early exploratory stage.

Quick Overview

Item	Content
Original Indication	Breast cancer (estrogen receptor antagonist / SERM class)
Predicted New Indication	HIV Infectious Disease
TxGNN Prediction Score	99.41%
Evidence Level	L4
Italy Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this Evidence Pack. Based on information derived from the supporting literature, Toremifene is a selective estrogen receptor modulator (SERM) of the same class as tamoxifen, with established clinical use in estrogen receptor-positive breast cancer. Its antitumour activity operates through hormone receptor blockade, but its molecular interactions extend beyond the endocrine system.

The mechanistic link to HIV Infectious Disease is indirect but biologically plausible. A 2014 preclinical study (PMID 24520056) demonstrated that SERM-class drugs — including toremifene — exhibit fungicidal activity against Cryptococcus neoformans by directly binding EF-hand calcium-binding proteins (calmodulin-like proteins) in the fungal cell, disrupting calcium signalling. Toremifene also synergized with fluconazole in vitro. Since cryptococcal meningitis is one of the most common and lethal opportunistic infections among AIDS patients, the model likely traces the pathway: HIV → immunocompromise → cryptococcal opportunistic infection → need for anti-cryptococcal agents.

It is important to emphasize that this is an indirect repurposing rationale — toremifene would target an HIV-related complication, not HIV itself. The entire evidence base currently rests on a single in vitro experiment with no clinical data in HIV patients, which significantly limits confidence in this prediction.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
24520056	2014	In vitro / Preclinical	mBio	Toremifene and tamoxifen are fungicidal against C. neoformans; both drugs bind EF-hand calcium proteins to disrupt fungal calcium signalling and synergize with fluconazole in vitro — supporting a potential role in HIV-associated cryptococcosis

Cytotoxicity

Toremifene is an antineoplastic agent (SERM class) used in breast cancer treatment.

Item	Content
Cytotoxicity Classification	Targeted hormonal therapy — Selective Estrogen Receptor Modulator (SERM)
Myelosuppression Risk	Low — SERMs do not typically cause clinically significant myelosuppression
Emetogenicity Classification	Low
Monitoring Items	QT/QTc interval (toremifene carries a known QT prolongation risk), liver function tests, endometrial assessment in female patients
Handling Protection	Standard precautions sufficient; not classified as a cytotoxic hazardous drug requiring specialized handling

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The entire evidence base consists of a single in vitro preclinical study from 2014; there are no registered clinical trials, no human data in HIV patients, and the mechanistic link is indirect — toremifene would address a cryptococcal opportunistic infection rather than HIV itself. The drug is also not marketed in Italy, adding a regulatory barrier.

To proceed, the following is needed:

Confirm official MOA and DrugBank pharmacological classification for toremifene
In vivo animal model data confirming anti-cryptococcal efficacy and tolerability in immunocompromised hosts
CNS pharmacokinetic/pharmacodynamic data (cryptococcal meningitis requires adequate CNS drug penetration)
Assessment of QT prolongation risk in HIV patients, who frequently co-receive other QT-prolonging antiretrovirals
At least one exploratory Phase 1/2 clinical trial in HIV patients with active or at-risk cryptococcal infection
Italian regulatory pathway review for repurposed or off-label use in this indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.